We think of this Supplement of the Journal of Infectious Diseases as a figurative manual of operations for how to build an airplane while flying it through a storm. The human toll of the Ebola virus disease (Ebola) epidemic of 2014-2016 was worse than that experienced in all previously recognized Ebola epidemics put together. The idea of testing experimental vaccines that were just entering Phase 1 studies in humans felt both essential and incredibly daunting, given the chaos of this epidemic and the setting of an ongoing epidemic where medical management and monitoring capacity were already strained and most commercial air carriers had cancelled routes. Nonetheless, our team of figurative airplane designers built the airplane, flew it, and landed it safely. Our airplane, the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) (Figure 1 ), forged strong partnerships between institutions in Sierra Leone and the broader public health and research community. With the successful collection of safety data on approximately 8000 vaccinated persons, the study findings also bring the world closer to having a safe and effective vaccine for preventing Ebola. Unlike previous Ebola outbreaks, which had generally been small and limited to remote, rural communities, this epidemic was huge and threatened an entire region. Ebola emerged in Guinea in March 2014 and then spread widely within Guinea and across borders into Liberia and Sierra Leone [1] . Early in the epidemic, cases occurred in Conakry, the capital of Guinea, the first time Ebola transmission had ever been reported in a major city. This was an ominous development given the size and density of the population; it meant that Ebola could spread more rapidly and extensively than it ever had before, and it also had profound repercussions for travel and trade [2] . By August 2014, Ebola was spreading rapidly in rural areas and had reached urban areas in all 3 highly affected West African countries. Case counts were increasing exponentially. Estimates of the future death toll were dire, highlighting the urgent need to rapidly scale up the ongoing control activities and to develop new tools for control and prevention [3] . The spread of Ebola to other countries in Africa, Europe, and the United States heightened fears and complicated humanitarian assistance. Despite aggressive efforts that were launched across West Africa during the last quarter of 2014 and continuing into 2016, approximately 29 000 cases and more than 11 000 deaths were reported throughout the region. These figures are likely a significant underestimate of the epidemic's true mortality and morbidity. Many survivors continue to contend with the substantial long-term health effects of Ebola [4] .
The Centers for Disease Control and Prevention (CDC) first sent staff to assist in Guinea in March 2014. In July, the agency activated its Emergency Operations Center and launched a largescale response that would stretch into 2016 [5] . Many CDC staff who deployed to West Africa in 2014 had extensive global public health experience including in natural disasters, epidemics, and famine, but they still returned home stunned by what they had seen and the challenges that affected countries faced with controlling the epidemic. In the fall of 2014, the CDC began plans to expand its Ebola response to include sponsoring a vaccine trial.
In late October 2014, CDC staff traveled to Sierra Leone to meet with the Ministry of Health and Sanitation (MOHS) and the College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, to discuss whether implementing an investigational vaccine trial would be possible in the midst of the epidemic. The higher risk of Ebola for healthcare workers had been recognized early in the Sierra Leone epidemic as these dedicated workers responded to the crisis. The CDC worked intensively with MOHS, COMAHS, and other key collaborators to begin planning a Phase 2/3 vaccine trial among healthcare and frontline Ebola response workers. This Phase 2/3 trial would test 1 of the 2 experimental Ebola vaccines selected after the Phase 1 trial data became available. The overarching goal of STRIVE was to accelerate the introduction of an Ebola vaccine among at-risk people in Sierra Leone while concurrently evaluating vaccine efficacy and safety. Guiding principles included starting the trial as soon as possible in the most-affected districts of Sierra Leone to provide as many people as possible the opportunity for protection. The study design and data-monitoring plan had to allow the flexibility to add study sites if the epidemiology of the epidemic changed and immediate recognition if the risk from the vaccine exceeded potential benefit to participants. It was also essential to extend the offer of vaccine to every participant by the end of the trial. Planning for the safety of participants who were volunteering to receive a product that had thus far been given to very few people was paramount [6] .
Rapidly planning and implementing STRIVE in the midst of the Ebola epidemic presented enormous challenges. One was making a final decision on which vaccine to test. The STRIVE researchers ultimately chose the recombinant vesicular stomatitis virus vaccine (rVSVΔG-ZEBOV-GP) (acquired by Newlink Genetics from Public Health Agency of Canada and later licensed to Merck & Co., Inc., Kenilworth, NJ); a major factor in this decision was that, because the vaccine was replication-competent, a single dose might provide both immediate and more durable protection. The limited healthcare infrastructure and clinical trial experience in Sierra Leone posed additional challenges. A cold chain to store and transport this vaccine at ≤−60°C had to be created and maintained. Facilities to enroll, vaccinate, and follow participants in 7 locations across 5 districts had to be built or renovated. An especially challenging but ultimately very successful and rewarding task was hiring and training more than 350 local staff while ensuring that such hiring did not interfere with Sierra Leone's Ebola response. Finally, given that the local population had limited understanding of Ebola disease and its prevention, communicating effectively and transparently was critical for gaining the trust of local communities. The STRIVE researchers had to ensure that potential participants understood that participation was voluntary and that the consent of those who decided to enroll was truly informed. The study was staffed by locally hired personnel who were supervised by the COMAHS Principal Investigator. They worked alongside CDC staff in Sierra Leone, the majority rotating on short-term assignments; CDC staff in Atlanta provided scientific, administrative, and logistical support. The US Biomedical Advanced Research and Development Authority, the National Institutes of Health, the US Embassy in Sierra Leone, the CDC Ebola Response Team in Sierra Leone and Atlanta, the CDC Foundation, eHealth Africa, The Emmes Corporation, FHI 360, Technical Resources, Inc., the World Health Organization, Global Good/Intellectual Ventures, and Modality Solutions all contributed critical skills and experience vital to STRIVE's success.
As trial planning proceeded, Ebola response efforts in Sierra Leone were already bringing the epidemic under control. The epidemic peaked in December 2014 and, by the time STRIVE was launched, Ebola incidence had declined to low levels. The first STRIVE participant was vaccinated on April 9, 2015, less than 6 months after the CDC's first exploratory trip to Sierra Leone. By December 2015, when vaccination was completed, STRIVE had vaccinated approximately 8000 healthcare and frontline workers. Safety follow-up was completed in 2016. No confirmed Ebola cases occurred among STRIVE participants, so we were unable to assess efficacy. The Sierra Leone epidemic was officially declared over in November 2015 with 14 112 reported cases and 4806 deaths, although new cases or small clusters emerged in the 3 highly affected countries as late as the spring of 2016.
In this Journal of Infectious Diseases supplement, we present STRIVE safety data from 6 months of postvaccination follow-up on approximately 8000 vaccinated persons. These data will support application for vaccine licensure. The additional 9 articles in this supplement summarize many of the experiences and lessons learned during STRIVE. Although the precise circumstances surrounding implementation of STRIVE are unlikely to recur, these reports may be informative for trial researchers and public health personnel facing research challenges amidst other epidemics. Topics include the following: overall study implementation; development and monitoring of a ≤−60°C cold chain for vaccine storage; communications strategies; development of a regulatory infrastructure in Sierra Leone to support a clinical trial of an investigational vaccine; systems put into place to monitor study participants for Ebola, vaccine safety, and participant retention; analysis of basic health data collected from participants during screening, enrollment, and follow-up; and the role of nurses in STRIVE.
CONCLUSIONS
One important objective of STRIVE was to build Sierra Leone's institutional capacity to lead clinical research of global importance. One of STRIVE's most important legacies is its contribution to the professional development of its talented Sierra Leonean research staff, some of whom have continued to work on other vaccine trials in Sierra Leone and others who are pursuing postgraduate education in public health and associated fields. The STRIVE infrastructure also provided permanent facilities for conducting trials and storing investigational vaccines. These staff and facilities can facilitate rapid emergency vaccination response efforts if Ebola re-emerges in Sierra Leone as it did in the Democratic Republic of the Congo in 2017. More broadly, the capacity built through the Ebola response and STRIVE supports the global health security agenda, which aims to strengthen each country's ability to prevent, detect, and respond to epidemics. In 2017, Sierra Leone was again struck by a catastrophe when heavy rains led to massive mudslides that wiped out entire neighborhoods. The emergency response capacity built during the Ebola epidemic facilitated the national authorities' incident response, which included a large-scale preventive cholera vaccination effort. Maintaining this enhanced preparedness capacity, through ongoing investments by the government of Sierra Leone and its partners, will reduce the chance that another public health crisis will cause nationwide repercussions as devastating and long-lasting as those that occurred as a result of the Ebola epidemic. 
